A peptide for prevention and treatment of COVID-19 in a patient, wherein the peptide consists of 7-17 amino acids and includes the hexamer TX1EX2X3E, wherein X1, X2 and X3 can be any natural or non-natural amino acid, and wherein the peptide does not exhibit TNF-receptor-binding activity. Suitable peptides include solnatide (cyclo-CGQRETPEGAEAKPWYC).
A cyclic polypeptide comprising at least six contiguous amino acids from the amino acid sequence SEQ ID NO: 1 Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr for the treatment of autosomal recessive pseudohypoaldosteronism type 1 (PHA type1B) or for the restoration of the Na+ transport capacity of mutated loss-of-function ENaC.
1231233 can be any natural or non-natural amino acid, and wherein the peptide does not exhibit TNF-receptor- binding activity, for use in prevention or treatment of COVID-19 in a patient. Solnatide (cyclo-CGQRETPEGAEAKPWYC) is a preferred peptide for use in the present invention.
2 comprises one amino acid, selected from natural amino acids; and a pharmaceutical composition, comprising a peptide of formula I as defined in any one of claims 1 to 7, in in a form, which is appropriate for spraying to obtain an aerosol for inhalation, or which is appropriate for the preparation of a spray to obtain an aerosol upon spraying, which is appropriate for inhalation.
3 can be any natural or non-natural amino acid, and the peptide is cyclized and does not exhibit TNF receptor binding activity, and an inhibitor of viral neuraminidase.
A cyclic polypeptide comprising at least six contiguous amino acids from the amino acid sequence SEQ ID NO:1 Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr for the treatment of autosomal recessive pseudohypoaldosteronism type 1 (PHA type1B) or for the restoration of the Na transport capacity of mutated loss-of-function ENaC.
A peptide is described, which consists of 7-17 adjacent amino acids and comprises the hexamer TXEXXE, wherein X, X and X can be any natural or non-natural amino acid, wherein the peptide has no TNF receptor binding activity and is cyclized, for the prevention and treatment of hyperpermeability of epithelial cells and endothelial cells.
Disclosed is a dry-powder peptide medicament with a non-typical concentration of carbohydrate excipient, as well as said medicament for use in treatment or prevention of a disease or condition, as well as methods for manufacturing said medicament.
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
A61K 31/7012 - Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
9.
CYCLIC POLYPEPTIDE FOR THE TREATMENT OF PHA TYPE 1B
A cyclic polypeptide comprising at least six contiguous amino acids from the amino acid sequence SEQ ID NO:1 Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr for the treatment of autosomal recessive pseudohypoaldosteronism type 1 (PHA type 1B) or for the restoration of the Na+ transport capacity of mutated loss-of-function ENaC.
C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
C07K 7/60 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
A61P 5/40 - Mineralocorticosteroids, e.g. aldosteroneDrugs increasing or potentiating the activity of mineralocorticosteroids
Cyclic peptide of formula
2 the C-terminal amino acid in the ultimate, right position, in the form of a lyophilisate without additives and/or stabilizers and its use.
Disclosed is a dry-powder peptide medicament with a non-typical concentration of carbohydrate excipient, as well as said medicament for use in treatment or prevention of a disease or condition, as well as methods for manufacturing said medicament.
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A cyclized compound of the amino acid sequence of formula X1 -GQRETPEGAEAKPWY-X2 wherein X1 comprises an amino acid (sequence) with 1 to 4, in particular 1 to 3 members, comprising natural or unnatural amino acids, in particular selected from the amino acid (sequence) C, KSP, K, ornithin, 4-amino butanoic acid, β-alanine, and X2 comprises one amino acid, selected from natural amino acids, in particular selected from the group C, D, G and E, and wherein X comprises the N-terminal amino acid at ist first left position and X2 comprises the C-terminal amino acid at its last right position, optionally in the form of a salt for use in the treatment of inflammation, a pharmaceutical composition for treating inflammation comprising such compound and a method of treating inflammation comprising administering an effective amount of such compound to a mammal in need thereof.
3 may be any natural or unnatural amino acid, where the peptide does not have any TNF receptor binding activity and is cyclized, for use for the treatment and avoidance of the pulmonary form of altitude sickness.
A cyclic peptide of forumula (I) X1-GQRETPEGAEAKPWY-X2, wherein X1 comprises an amino acid (sequence) with 1 to 4 members, including natural or unnatural amino acids, and X2 comprises a natural amino acid, and wherein X1 contains the N-terminal amino acid on the left in position 1, and X2 contains the C-terminal amino acid in the last position on the right, in the form of a lyophilisate without additives and/or stabilizers and the use thereof.
A method of conditioning/improving lung functions extracorporeally by treatment of a lung ex vivo with a cyclized compound of the amino acid sequence of formula I: X1-GQRETPEGAEAKPWY-X2 wherein X1 comprises an amino acid (sequence) with 1 to 4 members, comprising natural or unnatural amino acids, and X2 comprises one amino acid, selected from natural amino acids; and a pharmaceutical composition, comprising a peptide of formula I as defined in any one of claims 1 to 7, in in a form, which is appropriate for spraying to obtain an aerosol for inhalation, or which is appropriate for the preparation of a spray to obtain an aerosol upon spraying, which is appropriate for inhalation.
What is described is a peptide which consists of 7‑20, especially 7‑17, adjacent amino acids and comprises the hexamer TX1EX2X3E where X1, X2 and X3 may be any natural or unnatural amino acid, where the peptide does not have any TNF receptor binding activity and is cyclized, for use for the treatment and avoidance of the pulmonary form of altitude sickness.
3 can be any natural or non-natural amino acid, and the peptide is cyclized and does not exhibit TNF receptor binding activity, and—an inhibitor of viral neuraminidase.
3 can be any natural or non natural amino acid, wherein the peptide does not exhibit TNF-receptor-binding activity and is cyclic, for the treatment or prevention of vascular complications in diabetes patients.
A cyclic organic compound which comprises 16 amino acids or 17 amino acids and has no carboxyl group C-terminally and/or no amino group N-terminally. Optionally, one of the amino acids is a nonnatural amino acid. The ring closure is formed between a side chain of one amino acid and the C-terminus of another amino acid, or the ring closure is effected with the aid of a nonnatural amino acid. A process for producing and using the compound for regulating vectorial ion channels, for treating diseases associated with the lung function and for treating oedemas is provided.
Described is a composition comprising - a peptide which consists of 7-17 adjacent amino acids and comprises the hexamer TX1EX2X3E, where X1, X2 and X3 can be any natural or non-natural amino acid, and the peptide is cyclized and does not exhibit TNF receptor binding activity, and - an inhibitor of viral neuraminidase.
A peptide consisting of 7-17 amino acids and including the adjacent hexamer TX1EX2X3E, where X1, X2 and X3 can be any natural or non natural amino acid, wherein the peptide does not exhibit TNF-receptor-binding activity and is cyclic, for the treatment or prevention of vascular complications in diabetes patients.
The invention relates to a cyclic organic compound which comprises 16 amino acids or 17 amino acids and has no carboxylic group on the C-terminal end and/or no amino group on the N-terminal end, wherein, if necessary, one of the amino acids is a non-natural amino acid, and wherein the ring closure is formed between a side chain of an amino acid with the C-terminus of another amino acid, or the ring closure is carried out using a non-natural amino acid. The invention also relates to a method for the production thereof and the use thereof for the regulation of vectorial ion channels, the treatment of diseases that are associated with the pulmonary function and the treatment of oedema.
C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
A protein selected from the amino acid sequence of the region valine Val(91) to glycine Gly(121) of the mature human tumor necrosis factor, or a portion thereof, with the proviso that the protein comprises at least the amino acid sequence of the region lysine Lys(98) to glutamic acid Glu(116), with the cysteine Cys(101) being replaced by a glycine and an amide bond being formed between the amino group of the side chain of the lysine Lys(98) and the carboxyl group of the side chain of the glutamic acid Glu(116), which activates epithelial ion channels and improves the lung function and which can be used for the manufacture of medicaments for the treatment of diseases associated with the lung function, such as oedemas.
A protein which is composed N-terminally of one or several C-terminal parts of the amino acid sequence of the mature tumor necrosis factor and C-terminally of one or several N-terminal parts of the amino acid sequence of the mature tumor necrosis factor, which activates epithelial ion channels and improves the lung function and which can be used for the manufacture of medicaments for the treatment of diseases associated with the lung function, such as oedemas.
The invention relates to a peptide consisting of 7-17 adjoining amino acids and comprising the hexamer TX1EX2X3E, where X1, X2 and X3 can each be a natural or non-natural amino acid, wherein the peptide has no TNF receptor binding activity and is cyclized, for preventing and treating the hyperpermeability of epithelial cells and endothelial cells.
The invention relates to a protein which is selected from the amino acid sequence of the region valine Val(91) to glycine Gly(121) of the mature, human tumor necrosis factor, or a part thereof, provided that the protein comprises at least the amino acid sequence of the region lysine Lys(98) to glutamic acid Glu(116), the cysteine Cys(101) being replaced by a glycine and an amide bond being formed between the amino group of the side chain of the lysine Lys(98) and the carboxyl group of the side chain of the glutamic acid Glu(116). The protein activates epithelial ion channels and improves the pulmonary function and can be used to produce drugs for the treatment of diseases that are associated with the pulmonary function, such as oedema.
The invention relates to a protein the N-terminal end of which is composed of one or more C-terminal parts of the amino acid sequence of the mature tumor necrosis factor, and the C-terminal end of which is composed of one or more N-terminal parts of the amino acid sequence of the mature tumor necrosis factor. The protein activates epithelial ion channels and improves the pulmonary function and can be used to produce drugs for the treatment of diseases that are associated with the pulmonary function, such as oedema.
A protein selected from the amino acid sequence of the region valine Val(91) to glycine Gly(121) of the mature human tumour necrosis factor, or a portion thereof, with the proviso that the protein comprises at least the amino acid sequence of the region lysine Lys(98) to glutamic acid Glu(116), with the cysteine Cys(101) being replaced by a glycine and an amide bond being formed between the amino group of the side chain of the lysine Lys(98) and the carboxyl group of the side chain of the glutamic acid Glu(116), which activates epithelial ion channels and improves the lung function and which can be used for the manufacture of medicaments for the treatment of diseases associated with the lung function, such as oedemas.
A cyclic organic compound which comprises 16 amino acids or 17 amino acids and has no carboxyl group C-terminally and/or no amino group N-terminally, wherein, optionally, one of the amino acids is a nonnatural amino acid, and wherein the ring closure is formed between a side chain of one amino acid and the C-terminus of another amino acid, or the ring closure is effected with the aid of a nonnatural amino acid, a process for its production and its use for the regulation of vectorial ion channels, for the treatment of diseases associated with the lung function and for the treatment of oedemas.
A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
A cyclic peptide of forumula (I) X1-GQRETPEGAEAKPWY-X2, wherein X1 comprises an amino acid (sequence) with 1 to 4 members, including natural or unnatural amino acids, and X2 comprises a natural amino acid, and wherein X1 contains the N-terminal amino acid on the left in position 1, and X2 contains the C-terminal amino acid in the last position on the right, in the form of a lyophilisate without additives and/or stabilizers and the use thereof.
A method of conditioning/improving lung functions extracorporeally by treatment of a lung ex vivo with a cyclized compound of the amino acid sequence of formula I: X1-GQRETPEGAEAKPWY-X2 wherein X1 comprises an amino acid (sequence) with 1 to 4 members, comprising natural or unnatural amino acids, and X2 comprises one amino acid, selected from natural amino acids; and a pharmaceutical composition, comprising a peptide of formula I as defined in any one of claims 1 to 7, in in a form, which is appropriate for spraying to obtain an aerosol for inhalation, or which is appropriate for the preparation of a spray to obtain an aerosol upon spraying, which is appropriate for inhalation.
A peptide is described, which consists of 7-17 adjacent amino acids and comprises the hexamer TX EX X E, wherein X , X and X can be any natural or non-natural ~m~~ acid, where~n t2he pep~tide has no TNF receptor binding activity and is cyclized, for the prevention and treatment of hyperpermeability of epithelial cells and endothelial cells.
Described is a composition comprising - a peptide which consists of 7-17 adjacent amino acids and comprises the hexamer TX1EX2X3E, where X1, X2 and X3 can be any natural or non-natural amino acid, and the peptide is cyclized and does not exhibit TNF receptor binding activity, and - an inhibitor of viral neuraminidase.
